Colorado is currently home to 1917 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors
NCT04047251
Recruiting
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado
Conditions: Advanced Solid Tumors
Register for Updates
Pan Tumor Rollover Study
NCT03899155
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of Colorado, Aurora, Colorado
Conditions: Cancer
Register for Updates
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Register for Updates
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
NCT03145181
Recruiting
The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado
Conditions: Hematological Malignancies
Register for Updates
Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG
NCT03033992
Recruiting
This is a multicenter trial of the Optune device to examine the feasibility and to describe the device-related toxicity in children with supratentorial high grade glioma (HGG) or ependymoma (Stratum 1) and to examine the feasibility and efficacy of concurrent Optune and standard focal radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum 2).
Gender:
All
Ages:
Between 3 years and 21 years
Trial Updated:
06/18/2024
Locations: Children's Hospital of Colorado, Aurora, Colorado
Conditions: Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Register for Updates
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
NCT02997228
Recruiting
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado
Conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Register for Updates
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
NCT02932410
Recruiting
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
06/18/2024
Locations: Childrens Hospital Colorado, Aurora, Colorado
Conditions: Pulmonary Arterial Hypertension
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Aurora, Colorado
Conditions: Neoplasms
Register for Updates
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
NCT06435000
Recruiting
This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a multicenter study which will enroll approximately 75 subjects
Gender:
All
Ages:
Between 12 years and 65 years
Trial Updated:
06/17/2024
Locations: UCHealth Sue Anschutz-Rodgers Eye Center, Aurora, Colorado
Conditions: Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
Register for Updates
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531
Recruiting
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
06/17/2024
Locations: Rocky Mountain Movement Disorders Center, Denver, Colorado
Conditions: Progressive Supranuclear Palsy
Register for Updates
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
NCT06208306
Recruiting
This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments. The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide effi... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
06/17/2024
Locations: ~Alpine Clinical Research Center Site Number : 8401180, Boulder, Colorado
Conditions: Chronic Obstructive Pulmonary Disease
Register for Updates